# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Palantir (PLTR) stock surges due to inclusion in S&P 500 on Sept. 23 and new enterprise deal with BP. Technicals also show ...
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20240906-1474143/1474143_septembershuffle546.pdf
Wells Fargo analyst Brandon Couillard initiates coverage on Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight rating and a...
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announ...
RBC Capital analyst Conor McNamara reiterates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and maintains $401 price tar...
RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and lowers the price target f...
Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and raises the price target from...
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $3.11 per share which beat the analyst consensus estimate of $2....